Arrowhead Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Arrowhead Pharmaceuticals has a total shareholder equity of $382.0M and total debt of $263.1M, which brings its debt-to-equity ratio to 68.9%. Its total assets and total liabilities are $795.9M and $413.9M respectively.
Key information
68.9%
Debt to equity ratio
US$263.06m
Debt
| Interest coverage ratio | n/a |
| Cash | US$451.70m |
| Equity | US$381.99m |
| Total liabilities | US$413.87m |
| Total assets | US$795.86m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ARWR *'s short term assets ($470.2M) exceed its short term liabilities ($70.2M).
Long Term Liabilities: ARWR *'s short term assets ($470.2M) exceed its long term liabilities ($343.6M).
Debt to Equity History and Analysis
Debt Level: ARWR * has more cash than its total debt.
Reducing Debt: ARWR *'s debt to equity ratio has increased from 2.3% to 68.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARWR * has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ARWR * has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 27.1% each year.